Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?
Author:
Publisher
Elsevier BV
Subject
General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference63 articles.
1. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes;Polidori;Diabetologia,2014
2. The role of sodium-glucose Co-transporter 2 inhibitors in the treatment of type 2 diabetes;Whalen;Clin Ther,2015
3. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis;Baker;J Am Heart Assoc,2017
4. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes;Clar;BMJ Open,2012
5. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis;Shyangdan;BMJ Open,2016
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. XBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions;Cell & Bioscience;2024-02-22
2. Sotagliflozin attenuates liver associated disorders in cystic fibrosis rabbits;JCI Insight;2024-02-15
3. Liraglutide combined with routine therapy improves renal function, renal fibrosis, immune status, and prognosis of type 2 diabetes patients;American Journal of Translational Research;2024
4. A review of the last decade: pancreatic cancer and type 2 diabetes;Archives of Physiology and Biochemistry;2023-08-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3